Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.1%

3 terminated out of 27 trials

Success Rate

78.6%

-7.9% vs benchmark

Late-Stage Pipeline

11%

3 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed with results

Key Signals

3 with results79% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (8)
P 1 (3)
P 2 (3)
P 3 (2)
P 4 (1)

Trial Status

Completed11
Unknown6
Terminated3
Active Not Recruiting2
Recruiting2
Withdrawn1

Trial Success Rate

78.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT06995898Not ApplicableRecruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02305459CompletedPrimary

CIRSE Registry for SIR-Spheres Therapy

NCT04955808Suspended

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

NCT04288323Phase 4Completed

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT06717295Recruiting

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

NCT07046832Not ApplicableEnrolling By Invitation

Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy

NCT06966986Active Not RecruitingPrimary

Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma

NCT06720675CompletedPrimary

Ex-vivo Hypotermic Perfusion in Patients with Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence

NCT06789224Not ApplicableCompleted

Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device

NCT04682847Unknown

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

NCT06144385Phase 1UnknownPrimary

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

NCT02424955Not ApplicableCompleted

Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

NCT05681234Not ApplicableCompletedPrimary

Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

NCT04825470Not ApplicableUnknown

Liver Transplantation for Unresectable GIST Liver Metastases

NCT04443322Not ApplicableUnknownPrimary

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

NCT03775863CompletedPrimary

AFP Model and Liver Transplantation.

NCT03178409CompletedPrimary

Combined HCC-MFCCC

NCT01482442Phase 3CompletedPrimary

SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma

NCT01020812Phase 1Terminated

Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

Scroll to load more

Research Network

Activity Timeline